BofA raised the firm’s price target on Inspire Medical to $265 from $230 and keeps a Buy rating on the shares following what the firm calls out as the company’s first quarter with positive operating margins. Inspire reiterated revenue guidance for $775M-$785M, but gave new comments that it expects to move toward steady operating profitability as 2024 progresses, with profitability in the second half, noted the analyst.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on INSP:
- Lost Money in MBLY, BNTX, DADA, INSP or ON? Class Action Suits Filed, Seeking Recovery
- Inspire Medical Systems Engages Investors with Upcoming Meetings
- Inspire Medical Systems, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results and Reaffirms 2024 Outlook
- Inspire Medical resumed with an Overweight at KeyBanc
- Inspire Medical Announces Leadership Changes and New Chair
